Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 12,072

Document Document Title
WO/2011/137181A8
The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis ol...  
WO/2011/133227A2
The present invention synthetic oligo-β-(1→6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-β-(1→6)- glucosamine species having a definite number of monosaccharide units, including...  
WO/2011/133227A3
The present invention synthetic oligo-β-(1→6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-β-(1→6)- glucosamine species having a definite number of monosaccharide units, including...  
WO/2011/125057A4
The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and ...  
WO/2011/125057A1
The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and ...  
WO/2011/124986A3
In some aspects, the present invention provides aminoglycoside derivatives thereof that exhibit antibacterial activity. In some aspects, the aminoglycoside derivatives comprise compounds consisting of (a) an ammoglycoside group and (b) a...  
WO/2011/127179A1
Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof.  
WO/2011/118929A3
The present invention relates to the crystal form of Epirubicin hydrochloride stable against heat and water and the preparation method thereof. The novel crystal form has the physiochemical property stable against heat and water accordin...  
WO/2011/118929A2
The present invention relates to the crystal form of Epirubicin hydrochloride stable against heat and water and the preparation method thereof. The novel crystal form has the physiochemical property stable against heat and water accordin...  
WO/2011/113373A1
Disclosed is a method for ultrasonic extraction of stevioside. Crushed dry leaves of Stevia rebaudiana serve as raw material. Based on the characteristic that an ultrasonic cavitation can reinforce the extraction of active ingredients in...  
WO/2011/110721A1
The invention relates to a method for obtaining surfactants from cellulose and hemicellulose, which comprises one reaction in a single reactor (one pot) and which includes at least the following steps: e) a first hydrolysis step, in whic...  
WO/2011/100980A1
The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and th...  
WO/2011/100979A1
The present invention relates to a method for preparation of the trisaccharide 6'-0-sialyllactose (formula (I)) or salts thereof as well as intermediates in the synthesis and for the use of 6'-0-sialyllactose salts in pharmaceutical or n...  
WO/2011/098417A1
Substituted cyanobutyrates of the formula I in which the variables are defined according to the description, processes and intermediates for preparing the compounds of the formula I and their N-oxides, their agriculturally suitable salts...  
WO/2011/096536A1
Disclosed is a compound represented by general formula (1) or a salt thereof, which is capable of preferentially inducing the production of IFN-γ in NKT cells and is therefore useful for the prevention or treatment of cancer or infectio...  
WO/2011/096484A1
A read through inducer for an immature termination codon formed by a nonsense mutation, which comprises a compound represented by structure formula (A); and a therapeutic agent for nonsense-mutation-type genetic diseases, which comprises...  
WO/2011/096374A1
Provided is a novel iodobenzyl-bleomycin compound. Also provided are metal complexes that consist of the iodobenzyl-bleomycin compound and various metal atoms, such as an iodobenzyl-Co-bleomycin compound, that can accumulate on malignant...  
WO/2011/093471A1
Provided is a method for producing neoponkoranol or an analog thereof represented by structural formula [I] [wherein X- stands for a conjugated base of a Bronsted acid HX such as a carboxylate ion represented by R1COO-, a sulfonate ion r...  
WO/2011/094702A1
Steviol glycoside agglomerate compositions are disclosed that do not include binding agents or carriers.  
WO/2011/089602A3
The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageou...  
WO/2011/089561A1
A method of preparing a compound of formula (I): wherein: a first group selected from R1, R2 and R3 is an amino- or N-acylamino monosaccharide moiety, the acyl group having 1 to 6 carbon atoms, or an oligosaccharide chain comprising 2 to...  
WO/2011/088843A1
The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.  
WO/2011/089602A2
The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageou...  
WO/2011/085544A1
Compounds which effectively remove tumor or cancer cell and their use for the treatment and prevention of tumor or cancer by making immune system find tumor or cancer cell are provided. In detail, by immune identifier of tumor or cancer ...  
WO/2011/082288A1
Exemplary embodiments of this invention encompass a method for purifying a low purity steviol glycoside composition. In particular, this invention relates to a method for purifying low purity steviol glycoside compositions to obtain subs...  
WO/2011/076625A1
The invention relates to a sweetener and to a method for the production thereof.  
WO/2011/078383A1
Provided is a liquid-crystal compound which is usable as a base for injections. The compound is an amphipathic compound represented by general formula (I), wherein X and Y each represents a hydrogen atom or X and Y in cooperation represe...  
WO/2011/073112A3
Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infectio...  
WO/2011/073112A2
Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infectio...  
WO/2011/070592A3
The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates ...  
WO/2011/066653A1
Salacinol and ponkoranol homologues, derivatives thereof and methods of synthesizing and using said homologies and derivatives. The derivatives include stereoisomers, de-O-sulfonated compounds and congeners of the naturally occurring hom...  
WO/2011/058245A1
The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions com...  
WO/2011/058245A8
The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions com...  
WO/2011/058661A1
Provided is a method for extracting isosaponarin at a high concentration from wasabi (Wasabia japonica) leaves. Also provided is a method for extracting a material for foods, drugs and cosmetics. Isosaponarin is extracted at a high conce...  
WO/2011/055231A3
The invention describes substantially pure rebaudioside A polymorphs and processes to prepare them.  
WO/2011/056834A3
Thermally stable anhydrous Rebaudioside D can be provided by methods disclosed here and has been found to be more soluble in aqueous solutions than the previously known non-anhydrous Rebaudioside D. This physical property makes the anhyd...  
WO/2011/056834A2
Thermally stable anhydrous Rebaudioside D can be provided by methods disclosed here and has been found to be more soluble in aqueous solutions than the previously known non-anhydrous Rebaudioside D. This physical property makes the anhyd...  
WO/2011/052919A2
The present invention relates to alpga-galactosylceramide derivatives, to the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for an immune adjuvant, containing the derivativ...  
WO/2011/051520A1
The present invention relates to novel triterpenic saponins from the saffron (Crocus sativus L.) corm, a composition that comprises said saponins, the use thereof as adjuvant substances in protein vaccines, and also in the production of ...  
WO/2011/052919A3
The present invention relates to alpga-galactosylceramide derivatives, to the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for an immune adjuvant, containing the derivativ...  
WO/2011/048148A2
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/048148A3
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/044751A1
Foliamangiferosides having the general formula (I) are disclosed, wherein R is H or -OCH3. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds ...  
WO/2011/046057A1
Provided is a novel and non-natural sialic acid-containing sugar chain compound, which has a binding activity to a viral particle and remains stable even in the presence of sialidase, obtained by using a reaction with the use of a glycos...  
WO/2011/044498A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044538A1
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...  
WO/2011/044498A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044503A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044503A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044501A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  

Matches 401 - 450 out of 12,072